文献速递呼吸道感染

玛帕西沙韦治疗成人无并发症流感的Ⅱ期随机对照试验

[Efficacy and safety of pixavir marboxil for uncomplicated influenza in adults: a phase Ⅱ, randomized, double-blind, placebo-controlled clinical trial].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2026-01-01

该多中心、随机、双盲、安慰剂对照Ⅱ期试验纳入202例乙型流感成人患者,评估玛帕西沙韦40 mg、80 mg、40+40 mg单次给药方案的抗病毒效果与安全性。结果显示80 mg组病毒滴度转阴时间显著短于安慰剂组,40 mg组症状缓解时间显著缩短,各组不良事件发生率相近。

要点

  • 80 mg组病毒滴度转阴中位时间19.5 h,显著短于安慰剂组45.8 h(P=0.027)。
  • 40 mg组所有症状缓解中位时间37.7 h,显著短于安慰剂组68.2 h(P=0.009)。
  • 各组不良事件发生率13.5%~20.4%,未检出基线或治疗后耐药突变。

核心结论

  • 玛帕西沙韦单次给药在成人无并发症流感中显示感染性病毒学指标改善及临床症状缓解的潜在获益,总体耐受性良好。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照、平行分组、剂量范围Ⅱ期临床试验,纳入18~64岁急性无并发症流感成人202例。
  • 按1∶1∶1∶1随机分配至玛帕西沙韦40 mg、80 mg、40+40 mg或安慰剂组,按体重和基线症状评分分层。
  • 主要终点为RT-PCR流感病毒RNA转阴时间,疗效分析采用ITT感染人群(107例)和ITT人群(200例)。

主要发现

  • ITTI人群中,玛帕西沙韦各组RNA转阴中位时间28.2~42.4 h,安慰剂组48.1 h,差异均无统计学意义(均P>0.05)。
  • 病毒滴度转阴中位时间:80 mg组19.5 h(95%CI 15.17-22.80)、40 mg组22.6 h(95%CI 14.72-44.85)、40+40 mg组23.1 h(95%CI 18.63-26.98),安慰剂组45.8 h(95%CI 20.20-68.57),仅80 mg组差异有统计学意义(P=0.027)。
  • ITT人群中,40 mg组所有症状缓解中位时间37.7 h(95%CI 22.23-49.33)显著短于安慰剂组68.2 h(95%CI 47.70-97.17),P=0.009;80 mg组45.8 h(95%CI 34.50-62.67)差异无统计学意义。
  • 发热缓解中位时间:40 mg组24.1 h(95%CI 19.40-30.97)、80 mg组22.9 h(95%CI 19.48-27.00),分别较安慰剂组44.0 h(95%CI 34.67-50.85)缩短19.9 h和21.1 h(均P<0.001)。
  • 恢复至流感前健康状态中位时间:80 mg组127.7 h(95%CI 99.65-168.77)、40 mg组152.1 h(95%CI 105.55-171.83),分别较安慰剂组198.1 h(95%CI 167.10-210.52)缩短70.4 h和46.0 h(均P<0.05)。

关键数值与推荐

  • 入组标准:18~64岁,起病48 h内,腋温≥38.0 ℃,伴至少1项中重度流感症状,非重症且无重症高危因素。
  • 主要终点为RT-PCR流感病毒RNA转阴时间,次要终点包括症状缓解、病毒滴度转阴、发热缓解、健康状态恢复及不良事件。
  • 不良事件发生率:40 mg组13.5%、80 mg组18.0%、40+40 mg组20.4%、安慰剂组20.4%。

临床怎么用

  • 玛帕西沙韦单次给药在无并发症流感成人中耐受性良好,80 mg组在病毒滴度转阴方面显示优势。
  • 40 mg组在缩短症状缓解时间方面显示获益,发热缓解和健康状态恢复在40 mg及80 mg组均有改善。
  • 结果支持后续确证性临床试验,尚不能作为临床常规用药推荐。

局限性

  • 本研究为Ⅱ期剂量范围试验,样本量有限,主要终点RNA转阴时间组间差异无统计学意义。
  • 纳入人群仅为乙型流感成人患者,结果外推至甲型流感或其他人群需谨慎。
  • 部分次要终点组间差异未达统计学显著,需后续确证性试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the antiviral effect, clinical efficacy, safety and tolerability of pixavir marboxil in adult patients with acute, uncomplicated influenza. Methods: This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging phase Ⅱ clinical trial. Eligible participants were adults aged 18 to 64 years with acute, uncomplicated influenza, presenting within 48 hours of symptom onset with an axillary temperature ≥38.0 ℃ and ≥1 moderate-to-severe influenza symptom, who were neither severely ill nor at high risk for severe disease. Exclusion criteria included known hypersensitivity and recent antiviral use or vaccination. Participants were centrally randomized (1∶1∶1∶1) to oral pixavir marboxil (40 mg, 80 mg, or 40+40 mg) or placebo. Randomization was stratified by body weight (<80 kg vs.≥80 kg) and baseline influenza symptom score (<12 points vs.≥12 points). Rescue medications were permitted as clinically indicated during follow-up. The primary endpoint was the time to influenza virus RNA negativity by RT-PCR (time from first dose to the first RNA measurement below the lower limit of detection). Secondary endpoints included the time to relief of all influenza symptoms (severity scores of 0 or 1 for all 7 symptoms, sustained for ≥21.5 hours), time to cessation of infectious viral shedding by virus titer, time to resolution of fever, time to recovery to pre-influenza health status, changes from baseline in EQ-5D-5L scores, and the incidence of adverse events. Statistical analyses were performed using SAS 9.4. Efficacy was analyzed in the intention-to-treat infected (ITTI) and intention-to-treat (ITT) populations. Time-to-event data, including the primary endpoint, were estimated using the Kaplan-Meier method and compared between groups using the stratified Peto-Prentice generalized Wilcoxon test. Categorical data were analyzed using the Fisher's exact test or the Mantel-Haenszel test. Results: A total of 202 patients with influenza B were enrolled. In the ITTI population (107 cases), the median time to influenza virus RNA negativity was 28.2 h (95%CI: 19.73-43.88) in the 80 mg group, 35.5 h (95%CI: 23.43-45.05) in the 40 mg+40 mg group, and 42.4 h (95%CI: 22.60-57.53) in the 40 mg group, compared with 48.1 h (95%CI: 23.25-83.67) in the placebo group; between-group differences were not statistically significant (all P>0.05). The median times to cessation of infectious viral shedding by virus titer (TCID50) for the pixavir marboxil were [80 mg: 19.5 h (95%CI: 15.17-22.80); 40 mg: 22.6 h (95%CI: 14.72-44.85); 40 mg+40 mg: 23.1 h (95%CI: 18.63-26.98)] were versus the 45.8 h (95%CI: 20.20-68.57) in the placebo group; only the 80 mg group reached a statistically significant difference (P=0.027). In the ITT population (200 cases), pixavir marboxil 40 mg significantly shortened the median time to relief of all influenza symptoms compared to the placebo group [37.7 h (95%CI: 22.23-49.33) vs. 68.2 h (95%CI: 47.70-97.17), P=0.009], whereas the 80 mg group showed only a non-significant trend toward shortening 45.8 h [(95%CI: 34.50-62.67) vs. 68.2 h]. The median time to resolution of fever was significantly reduced in both the 40 mg [24.1 h (95%CI: 19.40-30.97)] and 80 mg [22.9 h (95%CI: 19.48-27.00)] groups compared with placebo [44.0 h (95%CI: 34.67-50.85)], with reductions of 19.9 h and 21.1 h, respectively (both P<0.001). The median time to recovery to pre-influenza health status was significantly shortened in the 80 mg [127.7 h (95%CI: 99.65-168.77)] and 40 mg [152.1 h (95%CI: 105.55-171.83)] groups compared with placebo [198.1 h (95%CI: 167.10-210.52)], with reductions of 70.4 h and 46.0 h, respectively (both P<0.05). The incidence of adverse events was comparable across groups: 13.5% (40 mg), 18.0% (80 mg), 20.4% (40 mg+40 mg), and 20.4% (placebo). No baseline or treatment-emergent resistance mutations were detected. Conclusion: Single-dose pixavir marboxil regimens demonstrated potential benefits in improving infectivity-related virologic measures and alleviating clinical symptoms in adults with uncomplicated influenza, with favorable overall tolerability. These findings provide a basis for subsequent confirmatory clinical trials. 目的: 评估玛帕西沙韦在急性流感病毒感染且无并发症的成人患者中的抗病毒效果、临床疗效、安全性和耐受性。 方法: 采用多中心、随机、双盲、安慰剂对照、平行分组、剂量范围的Ⅱ期临床试验,选择18~64岁、起病48 h内、腋温≥38 ℃伴至少一项中重度流感症状、非重症且无重症高危因素的流感患者,按1∶1∶1∶1中心化随机分配至玛帕西沙韦40 mg、80 mg、40 mg+40 mg或安慰剂组治疗。主要终点为流感病毒RNA转阴时间,次要终点主要包括所有流感症状缓解时间、流感病毒滴度转阴时间、发热缓解时间、恢复至流感前健康状况的时间、不良事件及病毒突变耐药等。主要终点及时间事件数据采用Kaplan-Meier法绘制生存曲线,组间比较采用分层Peto-Prentice广义Wilcoxon检验;计数资料采用Fisher精确概率法或Mantel-Haenszel检验。 结果: 共202例乙流患者入选本试验。对意向性治疗(intention-to-treat,ITT)感染人群(107例)分析,玛帕西沙韦各组流感病毒RNA转阴中位时间为28.2~42.4 h,安慰剂组为48.1 h,差异均无统计学意义(均P>0.05)。玛帕西沙韦各组流感病毒滴度转阴中位时间为19.5~23.1 h,安慰剂组为45.8 h,均显示出了加快病毒失活的作用,但仅80 mg组差异有统计学意义(P<0.05)。对ITT人群(200例)分析,相比安慰剂组,玛帕西沙韦40 mg可显著缩短所有流感症状缓解中位时间(37.7 h比68.2 h,P=0.009),80 mg组仅呈现缩短趋势(45.8 h比68.2 h),差异无统计学意义;在发热缓解中位时间上,40和80 mg组分别缩短了19.9和21.1h;对于恢复至流感前健康状况的中位时间,两组分别缩短了46.0和70.4 h,以上差异均有统计学意义(均P<0.05)。各组不良事件发生率相近(13.5%~20.4%),且所有参与者均未出现基线耐药或治疗后耐药突变。 结论: 玛帕西沙韦单次给药方案在成人无并发症流感患者中显示出感染性病毒学指标改善及临床症状缓解的潜在获益,且总体耐受性良好,为后续确证性临床试验提供了依据。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Chen MF, Sun YL, Yang Y, et al. [Efficacy and safety of pixavir marboxil for uncomplicated influenza in adults: a phase Ⅱ, randomized, double-blind, placebo-controlled clinical trial]. Zhonghua Jie He He Hu Xi Za Zhi. 2026. PMID: 42373447. doi:10.3760/cma.j.cn112147-20260210-00085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。